Investigating SYNM gene polymorphism as a risk model of a gene signature in predicting platinum response and survival in ovarian cancer.
Investigating SYNM gene polymorphism as a risk model of a gene signature in predicting platinum response and survival in ovarian cancer.
Shiva Mousavi Mirak,1,*Farnaz Farzaneh Dehkordi,2
1. Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran 2. Department of Biology, Ardabil Branch, Islamic Azad University, Ardabil, Iran
Introduction: Introduction: Ovarian cancer is one of the most deadly malignancies in women. Over time, tumors show resistance to these chemotherapy compounds and cause tumor recurrence and eventually resistance to treatment in more than 70 years. percentage of patients. Therefore, identifying people without response can be an important step towards increasing the survival of patients with ovarian cancer. Therefore, determining potential indicators such as specific biomarkers predicting platinum treatment response, which can help clinical decisions and improve prognosis, can be of vital importance.
Methods: Method and Materials: In this study, 50 samples of patients with ovarian cancer after chemotherapy and platinum-based treatment were examined and confirmed by a pathologist. Then the DNA of the samples was extracted by the kit and the SYNM gene polymorphism was analyzed by the Tetra-ARMS PCR technique
Results: Results: 50 patients were included in this study. The average age of the patients was 59.63 years. There was a significant relationship between the age of patients and ovarian cancer. In terms of neoplasia, the most involvement was on the right side (44%) of the patients. In terms of disease stage, (16%) patients who had bilateral involvement were in stage 2 of the disease, and the other patient with bilateral involvement was in stage 3 of the disease. In terms of histological grade, (14%) patients who had bilateral involvement and involved lymph nodes were in grade 3. Also (38%) who had bilateral involvement were in G2 stage in terms of histological grade. Among the patients, 10 cases (20%) had bilateral involvement and 40 cases (80%) had unilateral involvement. Also, among 40 patients with unilateral involvement, 18 cases (45%) had right-sided involvement and 22 cases (55%) had left-sided involvement. In terms of SYNM gene polymorphism, out of 50 patients, (42%) patients had polymorphism in SYNM gene.
Conclusion: Conclusion: The relationship between polymorphism and ovarian cancer was well determined in this study and the patients who were in more advanced stages of the disease.